[{"id":"f7e6df94-a121-41c2-ab20-30322990863a","acronym":"","url":"https://clinicaltrials.gov/study/NCT05327010","created_at":"2022-04-14T12:53:52.597Z","updated_at":"2025-02-25T14:02:49.505Z","phase":"Phase 2","brief_title":"Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial","source_id_and_acronym":"NCT05327010","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" KRAS • BRCA1 • BRCA2 • RAD51 • FANCA • BRIP1 • RAD51C • RAD51D • BARD1","pipe":" | ","alterations":" KRAS mutation • KRAS G12C • KRAS G12 • BRIP1 mutation • RAD51C mutation • RAD51D mutation • BARD1 mutation","tags":["KRAS • BRCA1 • BRCA2 • RAD51 • FANCA • BRIP1 • RAD51C • RAD51D • BARD1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12C • KRAS G12 • BRIP1 mutation • RAD51C mutation • RAD51D mutation • BARD1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Talzenna (talazoparib) • ZEN-3694"],"overall_status":"Recruiting","enrollment":" Enrollment 88","initiation":"Initiation: 11/14/2022","start_date":" 11/14/2022","primary_txt":" Primary completion: 08/04/2025","primary_completion_date":" 08/04/2025","study_txt":" Completion: 08/04/2025","study_completion_date":" 08/04/2025","last_update_posted":"2025-02-19"},{"id":"78af9b6a-0b92-4e92-b86c-385f5f7643c9","acronym":"","url":"https://clinicaltrials.gov/study/NCT04266912","created_at":"2021-01-18T20:43:57.460Z","updated_at":"2025-02-25T14:15:34.609Z","phase":"Phase 1/2","brief_title":"Avelumab and M6620 for the Treatment of DDR Deficient Metastatic or Unresectable Solid Tumors","source_id_and_acronym":"NCT04266912","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" BRCA1 • BRCA2 • ATM • ARID1A • BAP1 • MSH2 • CDK12 • ATRX • CHEK2 • SMARCB1 • RAD51 • FANCA • BRIP1 • RAD51C • CD4 • RAD51D • BARD1 • NBN • FANCF • FANCM • FANCD2 • FANCE • FANCC","pipe":"","alterations":" ","tags":["BRCA1 • BRCA2 • ATM • ARID1A • BAP1 • MSH2 • CDK12 • ATRX • CHEK2 • SMARCB1 • RAD51 • FANCA • BRIP1 • RAD51C • CD4 • RAD51D • BARD1 • NBN • FANCF • FANCM • FANCD2 • FANCE • FANCC"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Bavencio (avelumab) • berzosertib (M6620)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 25","initiation":"Initiation: 03/17/2020","start_date":" 03/17/2020","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-18"},{"id":"60bce1a2-b876-426c-a77f-15b4b5b443a9","acronym":"","url":"https://clinicaltrials.gov/study/NCT03805919","created_at":"2021-01-18T18:48:39.011Z","updated_at":"2025-02-25T15:34:18.012Z","phase":"","brief_title":"Men at High Genetic Risk for Prostate Cancer","source_id_and_acronym":"NCT03805919","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" TP53 • BRCA1 • BRCA2 • MLH1 • MSH6 • MSH2 • CHEK2 • FANCA • BRIP1 • RAD51C • RAD51D • EPCAM • NBN • FANCF • FANCL • FANCI • FANCM • FANCD2 • FANCE • FANCG • FANCB • FANCC • HOXB13","pipe":"","alterations":" ","tags":["TP53 • BRCA1 • BRCA2 • MLH1 • MSH6 • MSH2 • CHEK2 • FANCA • BRIP1 • RAD51C • RAD51D • EPCAM • NBN • FANCF • FANCL • FANCI • FANCM • FANCD2 • FANCE • FANCG • FANCB • FANCC • HOXB13"],"overall_status":"Recruiting","enrollment":" Enrollment 500","initiation":"Initiation: 03/27/2019","start_date":" 03/27/2019","primary_txt":" Primary completion: 01/01/2029","primary_completion_date":" 01/01/2029","study_txt":" Completion: 01/01/2039","study_completion_date":" 01/01/2039","last_update_posted":"2025-02-10"},{"id":"d4a8f858-34d0-4450-b14d-4588fe783648","acronym":"","url":"https://clinicaltrials.gov/study/NCT05687110","created_at":"2023-01-18T15:59:52.715Z","updated_at":"2025-02-25T16:54:40.188Z","phase":"Phase 1","brief_title":"Studying the Safety and Determining the Optimal Dose of Novobiocin in Patients With Tumors That Have Alterations in DNA Repair Genes","source_id_and_acronym":"NCT05687110","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRCA1 • BRCA2 • CDK12 • FANCA • RAD51B • BRIP1 • RAD51C • RAD50 • RAD51D • BARD1 • NBN • FANCF • FANCM • FANCD2 • FANCE • FANCC","pipe":" | ","alterations":" ATM mutation • PALB2 mutation • CDK12 mutation • BRIP1 mutation • RAD51C mutation • RAD51D mutation • RAD51B mutation • BARD1 mutation","tags":["BRCA1 • BRCA2 • CDK12 • FANCA • RAD51B • BRIP1 • RAD51C • RAD50 • RAD51D • BARD1 • NBN • FANCF • FANCM • FANCD2 • FANCE • FANCC"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ATM mutation • PALB2 mutation • CDK12 mutation • BRIP1 mutation • RAD51C mutation • RAD51D mutation • RAD51B mutation • BARD1 mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 31","initiation":"Initiation: 07/06/2023","start_date":" 07/06/2023","primary_txt":" Primary completion: 08/01/2026","primary_completion_date":" 08/01/2026","study_txt":" Completion: 09/01/2026","study_completion_date":" 09/01/2026","last_update_posted":"2025-02-04"},{"id":"6365efdc-854e-4454-ba10-f28f09a5a11b","acronym":"PEPN2112","url":"https://clinicaltrials.gov/study/NCT05071209","created_at":"2021-10-08T11:53:44.641Z","updated_at":"2025-02-25T17:01:24.348Z","phase":"Phase 1/2","brief_title":"Elimusertib for the Treatment of Relapsed or Refractory Solid Tumors","source_id_and_acronym":"NCT05071209 - PEPN2112","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRCA1 • BRCA2 • ATM • MSH2 • CDK12 • WT1 • ATRX • CHEK2 • RAD51 • FANCA • POLD1 • FOXO1 • XRCC2 • ATF1 • PAX3","pipe":" | ","alterations":" PAX3-FOXO1 fusion","tags":["BRCA1 • BRCA2 • ATM • MSH2 • CDK12 • WT1 • ATRX • CHEK2 • RAD51 • FANCA • POLD1 • FOXO1 • XRCC2 • ATF1 • PAX3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PAX3-FOXO1 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e elimusertib (BAY 1895344)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 31","initiation":"Initiation: 12/22/2021","start_date":" 12/22/2021","primary_txt":" Primary completion: 09/30/2024","primary_completion_date":" 09/30/2024","study_txt":" Completion: 11/22/2025","study_completion_date":" 11/22/2025","last_update_posted":"2025-02-03"},{"id":"73183b76-400c-42da-8908-2c1fc21637ec","acronym":"OPTIMUM","url":"https://clinicaltrials.gov/study/NCT05222971","created_at":"2022-02-05T18:29:24.003Z","updated_at":"2025-02-25T17:37:35.916Z","phase":"Phase 2","brief_title":"Olaparib with or Without Durvalumab for DDR Gene Mutated Biliary Tract Cancer Following Platinum-based Chemotherapy","source_id_and_acronym":"NCT05222971 - OPTIMUM","lead_sponsor":"Asan Medical Center","biomarkers":" BRCA1 • BRCA2 • ATM • POLE • BAP1 • MLH1 • MSH6 • MSH2 • BRCA • CHEK2 • RAD51 • FANCA • BRIP1 • RAD51C • RAD50 • RAD51D • CHEK1 • BARD1 • NBN • XRCC2 • FANCD2 • GEN1","pipe":" | ","alterations":" ATM mutation • CHEK2 mutation • BRIP1 mutation • BARD1 mutation","tags":["BRCA1 • BRCA2 • ATM • POLE • BAP1 • MLH1 • MSH6 • MSH2 • BRCA • CHEK2 • RAD51 • FANCA • BRIP1 • RAD51C • RAD50 • RAD51D • CHEK1 • BARD1 • NBN • XRCC2 • FANCD2 • GEN1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ATM mutation • CHEK2 mutation • BRIP1 mutation • BARD1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Imfinzi (durvalumab)"],"overall_status":"Recruiting","enrollment":" Enrollment 62","initiation":"Initiation: 04/01/2022","start_date":" 04/01/2022","primary_txt":" Primary completion: 12/30/2025","primary_completion_date":" 12/30/2025","study_txt":" Completion: 12/30/2026","study_completion_date":" 12/30/2026","last_update_posted":"2025-01-28"},{"id":"dfa37710-8128-4c60-aefe-7507a106a2e0","acronym":"MK3475-A53","url":"https://clinicaltrials.gov/study/NCT05379972","created_at":"2022-05-18T11:57:02.291Z","updated_at":"2025-02-25T16:17:42.708Z","phase":"Phase 2","brief_title":"Study of SBRT/Olaparib Followed by Pembrolizumab/Olaparib in Gastric Cancers","source_id_and_acronym":"NCT05379972 - MK3475-A53","lead_sponsor":"University of Colorado, Denver","biomarkers":" HER-2 • BRCA1 • BRCA2 • PTEN • HRD • BAP1 • KMT2D • ATRX • CHEK2 • FANCA • BRIP1 • RAD50 • MLL2 • CHEK1 • BARD1 • NBN • WRN • FANCG • ABRAXAS1 • SLX4","pipe":" | ","alterations":" HRD","tags":["HER-2 • BRCA1 • BRCA2 • PTEN • HRD • BAP1 • KMT2D • ATRX • CHEK2 • FANCA • BRIP1 • RAD50 • MLL2 • CHEK1 • BARD1 • NBN • WRN • FANCG • ABRAXAS1 • SLX4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HRD"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Lynparza (olaparib)"],"overall_status":"Recruiting","enrollment":" Enrollment 26","initiation":"Initiation: 01/12/2023","start_date":" 01/12/2023","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2028","study_completion_date":" 12/01/2028","last_update_posted":"2024-11-26"},{"id":"0274e43f-cc0c-414e-9481-44dc1368c6ca","acronym":"","url":"https://clinicaltrials.gov/study/NCT05515575","created_at":"2022-09-08T14:56:05.365Z","updated_at":"2025-02-25T13:13:08.083Z","phase":"Phase 2","brief_title":"A Study of Niraparib in People With Soft Tissue Sarcoma Who Have Changes in Their Tumor DNA","source_id_and_acronym":"NCT05515575","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" BRCA1 • BRCA2 • CHEK2 • FANCA • RAD51B • BRIP1 • RAD51C • RAD50 • PARP1 • CHEK1 • BARD1 • NBN • FANCF • FANCL • XRCC2 • ERCC4 • FANCI • FANCM • RAD52 • FANCD2 • FANCE • FANCG • RAD23B • RECQL4 • RPA1 • ABRAXAS1 • FANCC • RAD54B • SLX4","pipe":"","alterations":" ","tags":["BRCA1 • BRCA2 • CHEK2 • FANCA • RAD51B • BRIP1 • RAD51C • RAD50 • PARP1 • CHEK1 • BARD1 • NBN • FANCF • FANCL • XRCC2 • ERCC4 • FANCI • FANCM • RAD52 • FANCD2 • FANCE • FANCG • RAD23B • RECQL4 • RPA1 • ABRAXAS1 • FANCC • RAD54B • SLX4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zejula (niraparib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 8","initiation":"Initiation: 08/23/2022","start_date":" 08/23/2022","primary_txt":" Primary completion: 08/01/2026","primary_completion_date":" 08/01/2026","study_txt":" Completion: 08/01/2026","study_completion_date":" 08/01/2026","last_update_posted":"2024-11-05"},{"id":"5b18e518-5abe-49ce-9ea4-7ddcd3927bd8","acronym":"SPORE","url":"https://clinicaltrials.gov/study/NCT04666740","created_at":"2021-01-19T20:43:48.854Z","updated_at":"2025-02-25T16:10:54.810Z","phase":"Phase 2","brief_title":"A Study of Pembrolizumab and Olaparib for People with Metastatic Pancreatic Ductal Adenocarcinoma and Homologous Recombination Deficiency or Exceptional Treatment Response to Platinum-Based Therapy","source_id_and_acronym":"NCT04666740 - SPORE","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" BRCA1 • BRCA2 • ATM • BAP1 • CHEK2 • RAD51 • FANCA • BRIP1 • RAD51C • RAD50 • BARD1 • NBN • ABRAXAS1 • FANCC","pipe":"","alterations":" ","tags":["BRCA1 • BRCA2 • ATM • BAP1 • CHEK2 • RAD51 • FANCA • BRIP1 • RAD51C • RAD50 • BARD1 • NBN • ABRAXAS1 • FANCC"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Lynparza (olaparib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 63","initiation":"Initiation: 12/18/2020","start_date":" 12/18/2020","primary_txt":" Primary completion: 01/01/2025","primary_completion_date":" 01/01/2025","study_txt":" Completion: 01/01/2025","study_completion_date":" 01/01/2025","last_update_posted":"2024-10-14"},{"id":"c4941059-797c-48e5-8562-88baff159bbc","acronym":"TBCRC 048","url":"https://clinicaltrials.gov/study/NCT03344965","created_at":"2021-01-17T17:24:38.311Z","updated_at":"2025-02-25T14:58:31.297Z","phase":"Phase 2","brief_title":"Olaparib in Metastatic Breast Cancer","source_id_and_acronym":"NCT03344965 - TBCRC 048","lead_sponsor":"Beth Israel Deaconess Medical Center","biomarkers":" PGR • BRCA1 • BRCA2 • BRCA • CHEK2 • FANCA • BRIP1 • RAD51C • RAD50 • RAD51D • BARD1 • NBN • FANCF • FANCM • FANCD2 • FANCE • FANCC","pipe":" | ","alterations":" HR positive • PALB2 mutation • PGR positive • BRCA mutation","tags":["PGR • BRCA1 • BRCA2 • BRCA • CHEK2 • FANCA • BRIP1 • RAD51C • RAD50 • RAD51D • BARD1 • NBN • FANCF • FANCM • FANCD2 • FANCE • FANCC"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • PALB2 mutation • PGR positive • BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 114","initiation":"Initiation: 04/01/2018","start_date":" 04/01/2018","primary_txt":" Primary completion: 07/30/2025","primary_completion_date":" 07/30/2025","study_txt":" Completion: 12/30/2025","study_completion_date":" 12/30/2025","last_update_posted":"2024-10-11"},{"id":"acd4fa6f-57f1-4f7a-8049-516c634a95f7","acronym":"PARPi-PANC","url":"https://clinicaltrials.gov/study/NCT05442749","created_at":"2022-07-05T14:54:24.995Z","updated_at":"2025-02-25T13:13:04.354Z","phase":"Phase 2","brief_title":"Niraparib As First Line Therapy with Metastatic Homologous Repair-deficient Pancreatic Cancer","source_id_and_acronym":"NCT05442749 - PARPi-PANC","lead_sponsor":"Centre Leon Berard","biomarkers":" BRCA1 • BRCA2 • FANCA • RAD51B • BRIP1 • RAD51C • RAD51D • BARD1 • NBN • RAD54L • FANCL • PPP2R2A • FANCD2","pipe":"","alterations":" ","tags":["BRCA1 • BRCA2 • FANCA • RAD51B • BRIP1 • RAD51C • RAD51D • BARD1 • NBN • RAD54L • FANCL • PPP2R2A • FANCD2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zejula (niraparib)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 10/28/2022","start_date":" 10/28/2022","primary_txt":" Primary completion: 01/15/2026","primary_completion_date":" 01/15/2026","study_txt":" Completion: 09/15/2026","study_completion_date":" 09/15/2026","last_update_posted":"2024-09-11"},{"id":"d7a0703a-8b1b-461b-a082-3de4e2b533f7","acronym":"","url":"https://clinicaltrials.gov/study/NCT03061188","created_at":"2021-01-17T18:03:06.477Z","updated_at":"2025-02-25T14:37:19.874Z","phase":"Phase 1","brief_title":"Phase I/Ib Study of Nivolumab \u0026 Veliparib in Patients With Advanced Solid Tumors \u0026 Lymphoma","source_id_and_acronym":"NCT03061188","lead_sponsor":"Northwestern University","biomarkers":" BRCA1 • BRCA2 • MSI • POLE • BAP1 • CDK12 • ERCC2 • CHEK2 • RAD51 • FANCA • POLD1 • RAD50 • CHEK1 • BARD1 • NBN • EMSY • FANCD2 • FANCE • PRKDC • FANCC","pipe":" | ","alterations":" MSI-H/dMMR • RAD50 mutation","tags":["BRCA1 • BRCA2 • MSI • POLE • BAP1 • CDK12 • ERCC2 • CHEK2 • RAD51 • FANCA • POLD1 • RAD50 • CHEK1 • BARD1 • NBN • EMSY • FANCD2 • FANCE • PRKDC • FANCC"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR • RAD50 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • veliparib (ABT-888)"],"overall_status":"Completed","enrollment":" Enrollment 15","initiation":"Initiation: 05/23/2017","start_date":" 05/23/2017","primary_txt":" Primary completion: 03/11/2018","primary_completion_date":" 03/11/2018","study_txt":" Completion: 08/04/2020","study_completion_date":" 08/04/2020","last_update_posted":"2024-06-12"},{"id":"b82d5afc-83e5-4037-9280-7d0e4dfd7f17","acronym":"NCI10217","url":"https://clinicaltrials.gov/study/NCT03842228","created_at":"2021-01-18T18:58:03.649Z","updated_at":"2024-07-02T16:35:02.758Z","phase":"Phase 1","brief_title":"Testing the Combination of the Anti-cancer Drugs Copanlisib, Olaparib, and MEDI4736 (Durvalumab) in Patients With Advanced Solid Tumors With Selected Mutations","source_id_and_acronym":"NCT03842228 - NCI10217","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PIK3CA • BRCA1 • BRCA2 • RAD51 • FANCA • RAD51B • BRIP1 • RAD51C • CD4 • RAD51D • BARD1 • NBN","pipe":" | ","alterations":" PIK3CA mutation • PTEN mutation • PALB2 mutation • CDK12 mutation • PIK3CA E545 • PIK3CA H1047 • BARD1 mutation • PIK3CA E542 • RAD51 mutation","tags":["PIK3CA • BRCA1 • BRCA2 • RAD51 • FANCA • RAD51B • BRIP1 • RAD51C • CD4 • RAD51D • BARD1 • NBN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PIK3CA mutation • PTEN mutation • PALB2 mutation • CDK12 mutation • PIK3CA E545 • PIK3CA H1047 • BARD1 mutation • PIK3CA E542 • RAD51 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Imfinzi (durvalumab) • Aliqopa (copanlisib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 108","initiation":"Initiation: 11/21/2019","start_date":" 11/21/2019","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-05-17"},{"id":"f976983e-6e5c-40aa-ba00-71e22eb80e0e","acronym":"ATRIUM","url":"https://clinicaltrials.gov/study/NCT05338346","created_at":"2022-04-21T15:55:20.706Z","updated_at":"2024-07-02T16:35:08.451Z","phase":"Phase 1","brief_title":"A Study of ATG-018 (ATR Inhibitor) Treatment in Patients With Advanced Solid Tumors and Hematological Malignancies","source_id_and_acronym":"NCT05338346 - ATRIUM","lead_sponsor":"Antengene Discovery Limited","biomarkers":" BRCA1 • BRCA2 • ATM • ARID1A • MSH2 • CDK12 • ATRX • CHEK2 • RAD51 • FANCA • RAD51B • BRIP1 • RAD51C • RAD51D • BARD1 • NBN • FANCF • FANCM • FANCD2 • FANCE • FANCC","pipe":" | ","alterations":" TP53 mutation • FANCF mutation","tags":["BRCA1 • BRCA2 • ATM • ARID1A • MSH2 • CDK12 • ATRX • CHEK2 • RAD51 • FANCA • RAD51B • BRIP1 • RAD51C • RAD51D • BARD1 • NBN • FANCF • FANCM • FANCD2 • FANCE • FANCC"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • FANCF mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ATG-018"],"overall_status":"Recruiting","enrollment":" Enrollment 88","initiation":"Initiation: 07/08/2022","start_date":" 07/08/2022","primary_txt":" Primary completion: 06/30/2024","primary_completion_date":" 06/30/2024","study_txt":" Completion: 06/30/2024","study_completion_date":" 06/30/2024","last_update_posted":"2024-04-22"},{"id":"784f7253-5a1d-4544-9fbf-f9c89407e818","acronym":"BrUOG 360","url":"https://clinicaltrials.gov/study/NCT04253262","created_at":"2021-01-18T20:40:05.687Z","updated_at":"2025-02-25T17:24:31.844Z","phase":"Phase 1/2","brief_title":"A Study of Copanlisib Combined With Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer","source_id_and_acronym":"NCT04253262 - BrUOG 360","lead_sponsor":"Brown University","biomarkers":" BRCA1 • BRCA2 • HRD • CDK12 • FANCA • RAD51B • BRIP1 • RAD51C • RAD51D • CHEK1 • BARD1 • RAD54L • FANCL • PPP2R2A","pipe":" | ","alterations":" BRIP1 mutation","tags":["BRCA1 • BRCA2 • HRD • CDK12 • FANCA • RAD51B • BRIP1 • RAD51C • RAD51D • CHEK1 • BARD1 • RAD54L • FANCL • PPP2R2A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRIP1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rubraca (rucaparib) • Aliqopa (copanlisib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 13","initiation":"Initiation: 04/03/2020","start_date":" 04/03/2020","primary_txt":" Primary completion: 01/01/2027","primary_completion_date":" 01/01/2027","study_txt":" Completion: 01/01/2027","study_completion_date":" 01/01/2027","last_update_posted":"2024-04-05"},{"id":"ae2fbbdf-1d9d-47eb-9888-dad360517475","acronym":"MATRIX","url":"https://clinicaltrials.gov/study/NCT05986071","created_at":"2023-08-14T15:09:50.416Z","updated_at":"2025-02-25T16:19:00.084Z","phase":"Phase 1/2","brief_title":"I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers","source_id_and_acronym":"NCT05986071 - MATRIX","lead_sponsor":"Institut Paoli-Calmettes","biomarkers":" HER-2 • ER • BRCA1 • BRCA2 • ATM • RB1 • ARID1A • CDK12 • ATRX • BRCA • CHEK2 • FANCA • RAD51B • BRIP1 • RAD51C • RAD51D • BARD1 • NBN • RAD54L • FANCL • PPP2R2A • ERCC4 • FANCD2 • XRCC1","pipe":" | ","alterations":" HR positive • HER-2 negative • ATM mutation • ARID1A mutation • PALB2 mutation","tags":["HER-2 • ER • BRCA1 • BRCA2 • ATM • RB1 • ARID1A • CDK12 • ATRX • BRCA • CHEK2 • FANCA • RAD51B • BRIP1 • RAD51C • RAD51D • BARD1 • NBN • RAD54L • FANCL • PPP2R2A • ERCC4 • FANCD2 • XRCC1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • HER-2 negative • ATM mutation • ARID1A mutation • PALB2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e fulvestrant • tuvusertib (M1774)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 57","initiation":"Initiation: 05/01/2024","start_date":" 05/01/2024","primary_txt":" Primary completion: 04/01/2027","primary_completion_date":" 04/01/2027","study_txt":" Completion: 10/15/2027","study_completion_date":" 10/15/2027","last_update_posted":"2024-03-29"},{"id":"691969a6-dc3e-4580-99bb-0a9ff4f0cef1","acronym":"NIRADO","url":"https://clinicaltrials.gov/study/NCT04779151","created_at":"2021-03-03T13:57:08.218Z","updated_at":"2024-07-02T16:35:12.913Z","phase":"Phase 2","brief_title":"Basket Trial Exploring the Efficacy and Safety of the Combination of Niraparib and Dostarlimab","source_id_and_acronym":"NCT04779151 - NIRADO","lead_sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","biomarkers":" HER-2 • BRCA1 • BRCA2 • IDH1 • IDH2 • ARID1A • PBRM1 • CDK12 • CHEK2 • RAD51 • FANCA • BRIP1 • RAD51C • RAD51D • ARID2 • BARD1 • NBN • RAD54L • DRD","pipe":" | ","alterations":" HER-2 positive • HER-2 amplification • DDR • PBRM1 mutation • CDK12 mutation • CHEK2 mutation • BRIP1 mutation • RAD51C mutation • FANCA mutation • RAD51D mutation • BARD1 mutation • NBN mutation • DRD","tags":["HER-2 • BRCA1 • BRCA2 • IDH1 • IDH2 • ARID1A • PBRM1 • CDK12 • CHEK2 • RAD51 • FANCA • BRIP1 • RAD51C • RAD51D • ARID2 • BARD1 • NBN • RAD54L • DRD"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 amplification • DDR • PBRM1 mutation • CDK12 mutation • CHEK2 mutation • BRIP1 mutation • RAD51C mutation • FANCA mutation • RAD51D mutation • BARD1 mutation • NBN mutation • DRD"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zejula (niraparib) • Jemperli (dostarlimab-gxly)"],"overall_status":"Suspended","enrollment":" Enrollment 51","initiation":"Initiation: 04/07/2021","start_date":" 04/07/2021","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2027","study_completion_date":" 12/01/2027","last_update_posted":"2024-03-26"},{"id":"e9a0c2de-92c2-4b8a-8b7f-5e473ce5f549","acronym":"ARIANES","url":"https://clinicaltrials.gov/study/NCT04276376","created_at":"2023-01-23T18:00:08.144Z","updated_at":"2024-07-02T16:35:12.843Z","phase":"Phase 2","brief_title":"Efficacy and Safety of the Combination of Rucaparib (PARP Inhibitor) and Atezolizumab (Anti-PD-L1 Antibody) in Patients With DNA Repair-deficient or Platinum-sensitive Solid Tumors","source_id_and_acronym":"NCT04276376 - ARIANES","lead_sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","biomarkers":" BRCA1 • BRCA2 • ATM • CDK12 • CHEK2 • RAD51 • FANCA • BRIP1 • RAD51C • IL2 • RAD51D • BARD1 • NBN • RAD54L • DRD","pipe":" | ","alterations":" DDR • CDK12 mutation • CHEK2 mutation • BRIP1 mutation • RAD51C mutation • FANCA mutation • RAD51D mutation • BARD1 mutation • NBN mutation • DRD","tags":["BRCA1 • BRCA2 • ATM • CDK12 • CHEK2 • RAD51 • FANCA • BRIP1 • RAD51C • IL2 • RAD51D • BARD1 • NBN • RAD54L • DRD"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e DDR • CDK12 mutation • CHEK2 mutation • BRIP1 mutation • RAD51C mutation • FANCA mutation • RAD51D mutation • BARD1 mutation • NBN mutation • DRD"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • Rubraca (rucaparib)"],"overall_status":"Suspended","enrollment":" Enrollment 130","initiation":"Initiation: 04/12/2019","start_date":" 04/12/2019","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 04/01/2025","study_completion_date":" 04/01/2025","last_update_posted":"2024-03-26"},{"id":"3fbcc4ad-a557-4826-93ff-485a91046175","acronym":"","url":"https://clinicaltrials.gov/study/NCT05967286","created_at":"2023-08-01T16:10:19.979Z","updated_at":"2024-07-02T16:35:13.626Z","phase":"Phase 2","brief_title":"Olaparib and Alpelisib for Treatment of Metastatic Breast Cancer, A ComboMATCH Treatment Trial","source_id_and_acronym":"NCT05967286","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2 • ER • PIK3CA • BRCA1 • BRCA2 • BAP1 • FANCA • RAD51B • BRIP1 • RAD51C • RAD50 • RAD51D • BARD1 • FANCF • FANCM • FANCD2 • FANCE • FANCC","pipe":" | ","alterations":" ER positive • HER-2 negative • PIK3CA mutation • ER negative","tags":["HER-2 • ER • PIK3CA • BRCA1 • BRCA2 • BAP1 • FANCA • RAD51B • BRIP1 • RAD51C • RAD50 • RAD51D • BARD1 • FANCF • FANCM • FANCD2 • FANCE • FANCC"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative • PIK3CA mutation • ER negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Piqray (alpelisib)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 10/23/2023","start_date":" 10/23/2023","primary_txt":" Primary completion: 04/30/2025","primary_completion_date":" 04/30/2025","study_txt":" Completion: 04/30/2025","study_completion_date":" 04/30/2025","last_update_posted":"2024-03-20"},{"id":"bd0915a0-fd20-4277-b54e-97bf1a6410c3","acronym":"","url":"https://clinicaltrials.gov/study/NCT03452774","created_at":"2021-01-18T17:01:36.578Z","updated_at":"2024-07-02T16:35:14.464Z","phase":"","brief_title":"SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry","source_id_and_acronym":"NCT03452774","lead_sponsor":"Massive Bio, Inc.","biomarkers":" EGFR • HER-2 • PD-L1 • KRAS • BRAF • ER • ALK • TP53 • TMB • FLT3 • ABL1 • NRAS • BRCA1 • BRCA2 • FGFR2 • PTEN • ROS1 • IDH1 • NTRK1 • BCL2 • IDH2 • NTRK3 • NTRK2 • STK11 • NPM1 • HRAS • DNMT3A • ERBB3 • RB1 • CLDN18 • PDGFRA • NF1 • JAK2 • NRG1 • POLE • AKT1 • PD-1 • CCND1 • MCL1 • KDR • PBRM1 • BAP1 • VEGFA • BCL6 • PDGFRB • PTCH1 • FGFR4 • MSH6 • CDK4 • MSH2 • CTNNB1 • MAP2K2 • FBXW7 • WT1 • ATRX • BRCA • RAF1 • TSC2 • CHEK2 • PD-L2 • ERBB4 • JAK1 • FANCA • TSC1 • MDM4 • POLD1 • CDK6 • CEBPA • PARP1 • AURKA • JAK3 • RICTOR • CHEK1 • GATA6 • MSH3 • TGFBR2 • GNAS • MYCL • AKT2 • CCND2 • CCND3 • CSF1R • MAP3K1 • ERCC4 • HDAC1 • PRDM1 • ZNF217 • CDKN1A • GATA3 • PARP2 • PARP3 • SDHA • ACVR1B • ZNF703","pipe":" | ","alterations":" HER-2 mutation • BAP1 mutation • AKT1 mutation • FGFR3 fusion • JAK3 mutation","tags":["EGFR • HER-2 • PD-L1 • KRAS • BRAF • ER • ALK • TP53 • TMB • FLT3 • ABL1 • NRAS • BRCA1 • BRCA2 • FGFR2 • PTEN • ROS1 • IDH1 • NTRK1 • BCL2 • IDH2 • NTRK3 • NTRK2 • STK11 • NPM1 • HRAS • DNMT3A • ERBB3 • RB1 • CLDN18 • PDGFRA • NF1 • JAK2 • NRG1 • POLE • AKT1 • PD-1 • CCND1 • MCL1 • KDR • PBRM1 • BAP1 • VEGFA • BCL6 • PDGFRB • PTCH1 • FGFR4 • MSH6 • CDK4 • MSH2 • CTNNB1 • MAP2K2 • FBXW7 • WT1 • ATRX • BRCA • RAF1 • TSC2 • CHEK2 • PD-L2 • ERBB4 • JAK1 • FANCA • TSC1 • MDM4 • POLD1 • CDK6 • CEBPA • PARP1 • AURKA • JAK3 • RICTOR • CHEK1 • GATA6 • MSH3 • TGFBR2 • GNAS • MYCL • AKT2 • CCND2 • CCND3 • CSF1R • MAP3K1 • ERCC4 • HDAC1 • PRDM1 • ZNF217 • CDKN1A • GATA3 • PARP2 • PARP3 • SDHA • ACVR1B • ZNF703"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 mutation • BAP1 mutation • AKT1 mutation • FGFR3 fusion • JAK3 mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 50000","initiation":"Initiation: 01/01/2018","start_date":" 01/01/2018","primary_txt":" Primary completion: 12/01/2026","primary_completion_date":" 12/01/2026","study_txt":" Completion: 06/01/2027","study_completion_date":" 06/01/2027","last_update_posted":"2024-03-15"},{"id":"1bada8c3-f2f1-4030-ad23-c27e1828e629","acronym":"","url":"https://clinicaltrials.gov/study/NCT04550494","created_at":"2021-01-18T21:45:36.970Z","updated_at":"2024-07-02T16:35:16.133Z","phase":"Phase 2","brief_title":"Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations","source_id_and_acronym":"NCT04550494","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRCA1 • BRCA2 • IDH1 • IDH2 • ARID1A • BAP1 • CDK12 • CHEK2 • RAD51 • FANCA • RAD51B • BRIP1 • RAD51C • RAD50 • RAD51D • CHEK1 • BARD1 • NBN • RAD54L • FANCF • FANCL • FANCI • FANCM • BACH1 • FANCD2 • FANCE • FANCG • FANCB • FANCC","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation • ATM mutation","tags":["BRCA1 • BRCA2 • IDH1 • IDH2 • ARID1A • BAP1 • CDK12 • CHEK2 • RAD51 • FANCA • RAD51B • BRIP1 • RAD51C • RAD50 • RAD51D • CHEK1 • BARD1 • NBN • RAD54L • FANCF • FANCL • FANCI • FANCM • BACH1 • FANCD2 • FANCE • FANCG • FANCB • FANCC"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation • ATM mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Talzenna (talazoparib)"],"overall_status":"Recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 04/26/2021","start_date":" 04/26/2021","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2024-03-06"},{"id":"914ea5fe-d76b-491e-9df1-f62ef69fc859","acronym":"PLATPARP","url":"https://clinicaltrials.gov/study/NCT04288687","created_at":"2021-01-18T14:26:42.299Z","updated_at":"2024-07-02T16:35:18.466Z","phase":"Phase 2","brief_title":"A Trial of Niraparib in Platinum-Sensitive Castration-Resistant Prostate Cancer With DNA Repair Defects","source_id_and_acronym":"NCT04288687 - PLATPARP","lead_sponsor":"Abramson Cancer Center at Penn Medicine","biomarkers":" BRCA1 • BRCA2 • CHEK2 • FANCA • BRIP1 • HDAC2","pipe":"","alterations":" ","tags":["BRCA1 • BRCA2 • CHEK2 • FANCA • BRIP1 • HDAC2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zejula (niraparib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 10/19/2020","start_date":" 10/19/2020","primary_txt":" Primary completion: 06/01/2024","primary_completion_date":" 06/01/2024","study_txt":" Completion: 06/01/2024","study_completion_date":" 06/01/2024","last_update_posted":"2024-02-21"},{"id":"7235b2f2-0818-493f-a41a-c34684bbba42","acronym":"TRIUMPH","url":"https://clinicaltrials.gov/study/NCT03413995","created_at":"2021-01-18T16:50:34.963Z","updated_at":"2024-07-02T16:35:19.977Z","phase":"Phase 2","brief_title":"Trial of Rucaparib in Patients With Metastatic Hormone-Sensitive Prostate Cancer Harboring Germline DNA Repair Gene Mutations","source_id_and_acronym":"NCT03413995 - TRIUMPH","lead_sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","biomarkers":" BRCA1 • BRCA2 • ATM • CHEK2 • FANCA • RAD51C • RAD50 • RAD51D • NBN • FANCF • FANCL • FANCI • FANCM • FANCD2 • FANCE • FANCG • FANCB • FANCC","pipe":" | ","alterations":" CHEK2 mutation • RAD51C mutation • FANCA mutation • RAD51D mutation • RAD50 mutation • FANCF mutation • NBN mutation • FANCG mutation • FANCI mutation • FANCM mutation","tags":["BRCA1 • BRCA2 • ATM • CHEK2 • FANCA • RAD51C • RAD50 • RAD51D • NBN • FANCF • FANCL • FANCI • FANCM • FANCD2 • FANCE • FANCG • FANCB • FANCC"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CHEK2 mutation • RAD51C mutation • FANCA mutation • RAD51D mutation • RAD50 mutation • FANCF mutation • NBN mutation • FANCG mutation • FANCI mutation • FANCM mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rubraca (rucaparib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 09/10/2018","start_date":" 09/10/2018","primary_txt":" Primary completion: 11/08/2023","primary_completion_date":" 11/08/2023","study_txt":" Completion: 09/01/2024","study_completion_date":" 09/01/2024","last_update_posted":"2024-02-09"},{"id":"40c981ff-8175-448f-9a83-1821f4e1666b","acronym":"DOLAF","url":"https://clinicaltrials.gov/study/NCT04053322","created_at":"2021-01-18T19:52:27.595Z","updated_at":"2024-07-02T16:35:20.853Z","phase":"Phase 2","brief_title":"Durvalumab, With Olaparib and Fulvestrant in Advanced ER+, HER2- Breast Cancer Patients.","source_id_and_acronym":"NCT04053322 - DOLAF","lead_sponsor":"UNICANCER","biomarkers":" HER-2 • ER • BRCA1 • BRCA2 • MSI • CDK12 • BRCA • CHEK2 • FANCA • RAD51B • BRIP1 • RAD51C • CHEK1 • BARD1 • NBN • RAD54L • FANCL • PPP2R2A","pipe":" | ","alterations":" ER positive • BRCA1 mutation • HER-2 negative • FANCA deletion","tags":["HER-2 • ER • BRCA1 • BRCA2 • MSI • CDK12 • BRCA • CHEK2 • FANCA • RAD51B • BRIP1 • RAD51C • CHEK1 • BARD1 • NBN • RAD54L • FANCL • PPP2R2A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • BRCA1 mutation • HER-2 negative • FANCA deletion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Imfinzi (durvalumab) • fulvestrant"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 172","initiation":"Initiation: 08/26/2019","start_date":" 08/26/2019","primary_txt":" Primary completion: 11/15/2023","primary_completion_date":" 11/15/2023","study_txt":" Completion: 08/01/2027","study_completion_date":" 08/01/2027","last_update_posted":"2024-02-05"}]